AU Patent

AU2012216590A1 — Modified-release formulations of a bupropion salt

Assigned to Valeant International Bermuda · Expires 2012-09-20 · 14y expired

What this patent protects

C:\RPorh\D DAR\576625_ .DOC-IMM0//2012 The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupr…

USPTO Abstract

C:\RPorh\D DAR\576625_ .DOC-IMM0//2012 The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition. 0.030 - 100 0.45---mmm------------- -------------------- -o 0.040 --------- -------------- 0-025 -------.- - --- -- -.--- ---- ------------ -- ----------- 7 C-------------------------------------------- ------- - 30 .0--- -- ------------------- --- ~ ~--------- ~0 0.005 --------- --------------.....- ---------------- -10 0 so 120 I80 240 300 360 time (mins)

Drugs covered by this patent

Patent Metadata

Patent number
AU2012216590A1
Jurisdiction
AU
Classification
—
Expires
2012-09-20
Drug substance claim
No
Drug product claim
No
Assignee
Valeant International Bermuda
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.